<div id="readability-page-1"><div><h2>Insider selling puts Harrow (HROW) under the microscope</h2> <p>Heavy insider selling at Harrow (HROW) has caught investor attention after company insiders sold about US$8.1 million of stock over the past 3 months, with no reported insider purchases.</p> <p>This activity comes as Harrow shares recently fell 3.6% to US$35.93. At the same time, external models such as GuruFocus’s GF Value suggest the stock may be modestly undervalued, creating a tension between insider behavior and valuation signals.</p> <p>See our latest analysis for Harrow.</p> <p>Harrow’s recent share price rebound to US$37.10, with a 1 day share price return of 3.26% and a 1 month share price return of 8.80%, contrasts with a weaker 90 day share price return of a 21.38% decline, while the 1 year total shareholder return of 52.05% points to stronger longer term performance.</p> <p>If insider selling has you rethinking concentration risk, it could be a good moment to broaden your watchlist and check out 18 top founder-led companies</p> <p>With Harrow trading around US$37.10, some external models flag a discount to estimated value. However, heavy insider selling points the other way. Is there genuine upside left here, or is the market already pricing in future growth?</p> <h2>Most Popular Narrative: 47.5% Undervalued</h2> <p>With Harrow last closing at $37.10 and the most followed narrative pointing to a fair value around $70.63, the gap between price and projected potential is wide enough to warrant a closer look at what is driving that view.</p> <blockquote> <p><em>The rapidly growing demand for Harrow's portfolio of specialty ophthalmic drugs, particularly VEVYE, IHEEZO, and TRIESENCE, is positioned to accelerate further as aging populations and increased prevalence of chronic ocular diseases expand the baseline patient pool supporting sustainable long-term revenue growth.</em></p> </blockquote> <p><em>Read the complete narrative.</em></p> <p>Curious what kind of revenue build, margin lift, and future earnings multiple are baked into that fair value? The narrative leans on aggressive top line compounding, a step change in profitability, and a valuation framework that assumes Harrow earns a place among higher quality growth names without spelling out every assumption up front.</p> <p><strong>Result: Fair Value of $70.63 (UNDERVALUED)</strong></p> <p>Have a read of the narrative in full and understand what's behind the forecasts.</p> <p>However, this upside story still leans heavily on a few key drugs and ambitious margin targets, where slower uptake or pricing pressure could quickly challenge the thesis.</p> <p>Find out about the key risks to this Harrow narrative.</p> <h2>Next Steps</h2> <p>With mixed signals on insider sentiment and valuation, this is the moment to look at the data yourself and decide where you stand. Start with the 2 key rewards.</p> <h2>Looking for more investment ideas?</h2> <p>Do not stop your research at one company. Broaden your opportunity set now with targeted stock ideas that match what you want your portfolio to achieve.</p> <ul> <li>Target potential upside with companies that combine quality and attractive pricing by reviewing 55 high quality undervalued stocks.</li> <li>Build a steadier income stream by focusing on companies offering robust yields using 10 dividend fortresses.</li> <li>Prioritize resilience by concentrating on businesses with stronger finances through solid balance sheet and fundamentals stocks screener (41 results).</li> </ul> <p><em> This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data     and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your     financial situation. We aim to bring you long-term focused analysis driven by fundamental data.     Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.     Simply Wall St has no position in any stocks mentioned.</em></p><div><h3>Valuation is complex, but we're here to simplify it.</h3><p>Discover if Harrow might be undervalued or overvalued with our detailed analysis, featuring <strong>fair value estimates, potential risks, dividends, insider trades, and its financial condition.</strong></p><p>Access Free Analysis</p></div></div></div>

HROW

<p>Harrow (HROW) faces scrutiny due to heavy insider selling, with insiders offloading $8.1 million in stock over three months and no purchases reported. Despite a recent share price rebound to $37.10, the stock has seen a 21.38% decline over 90 days. External models suggest it may be undervalued, with a fair value estimate of $70.63. The company's growth is driven by demand for specialty ophthalmic drugs, but risks remain regarding key drugs and market pressures. Investors are encouraged to assess their positions amid mixed signals on insider sentiment and valuation.</p>

Simplywall

Harrow

Invesco Biotechnology & Genome ETF

Proshares Ultra Nasdaq Biotech

ALPS Medical Breakthrough

SPDR Pharmac

VanEck Biotech ETF

Direxion S&P Biotech Bull 3X

VG Health

SPDR S&P Biotech

Ark Genomic Revolution ETF

iShares Biotechnology ETF

First Trust NYSE Arca Biotech Index Fd

iShares US Pharma

Health Care Select Sector SPDR

Assessing Harrow (HROW) Valuation As Heavy Insider Selling Tests The Undervaluation Story